[go: up one dir, main page]

PL2621468T3 - Kompozycja farmaceutyczna karbetocyny - Google Patents

Kompozycja farmaceutyczna karbetocyny

Info

Publication number
PL2621468T3
PL2621468T3 PL11776530T PL11776530T PL2621468T3 PL 2621468 T3 PL2621468 T3 PL 2621468T3 PL 11776530 T PL11776530 T PL 11776530T PL 11776530 T PL11776530 T PL 11776530T PL 2621468 T3 PL2621468 T3 PL 2621468T3
Authority
PL
Poland
Prior art keywords
carbetocin
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL11776530T
Other languages
English (en)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2621468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL2621468T3 publication Critical patent/PL2621468T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
PL11776530T 2010-09-30 2011-09-29 Kompozycja farmaceutyczna karbetocyny PL2621468T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
EP11776530.5A EP2621468B1 (en) 2010-09-30 2011-09-29 Pharmaceutical composition of carbetocin

Publications (1)

Publication Number Publication Date
PL2621468T3 true PL2621468T3 (pl) 2017-11-30

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17169328T PL3222272T3 (pl) 2010-09-30 2011-09-29 Kompozycje farmaceutyczne karbetocyny
PL11776530T PL2621468T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna karbetocyny
PL17169301T PL3246018T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17169328T PL3222272T3 (pl) 2010-09-30 2011-09-29 Kompozycje farmaceutyczne karbetocyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17169301T PL3246018T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna

Country Status (27)

Country Link
US (4) US9566311B2 (pl)
EP (5) EP2621468B1 (pl)
JP (2) JP6038797B2 (pl)
KR (2) KR102102664B1 (pl)
CN (4) CN107080832B (pl)
AU (1) AU2011309762B2 (pl)
BR (2) BR122021001123B1 (pl)
CA (1) CA2812510A1 (pl)
CY (2) CY1119245T1 (pl)
DK (3) DK2621468T3 (pl)
ES (3) ES2902418T3 (pl)
HK (1) HK1246170A1 (pl)
HR (2) HRP20211969T1 (pl)
HU (3) HUE057187T2 (pl)
IL (3) IL225238B (pl)
JO (3) JO3400B1 (pl)
LT (2) LT3222272T (pl)
MX (1) MX352949B (pl)
NZ (1) NZ609719A (pl)
PL (3) PL3222272T3 (pl)
PT (3) PT3246018T (pl)
RS (2) RS62873B1 (pl)
RU (2) RU2604690C2 (pl)
SI (3) SI3222272T1 (pl)
SM (2) SMT202200034T1 (pl)
TW (6) TWI750934B (pl)
WO (1) WO2012042371A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846810A4 (en) * 2012-05-08 2016-04-13 Dilafor Ab TREATMENT OF AFTERBREAD BLOOMING WITH CHEMICALLY MODIFIED HEPARIN OR HEPARANSULFATE AND ONE UTEROTONIC AGENT
FI3666258T3 (fi) * 2014-09-19 2024-02-09 Ferring Bv Menetelmä prader-willin oireyhtymän hoitamiseksi
CN106999436B (zh) 2014-10-01 2021-07-02 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
CN107106640B (zh) * 2014-10-01 2021-06-15 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
WO2017180781A1 (en) 2016-04-12 2017-10-19 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
US10981955B2 (en) * 2017-08-11 2021-04-20 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
JP2021515005A (ja) 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
WO2020128499A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
JP7579811B2 (ja) 2019-05-22 2024-11-08 バイオヴァイ インコーポレイテッド テルリプレシンの製剤
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
MX2021015732A (es) 2019-11-04 2022-01-24 Ferring Bv Administracion intranasal de merotocina para mejorar la lactancia.
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
EP4313106B1 (en) 2021-03-26 2025-01-15 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
US12214010B2 (en) 2023-04-04 2025-02-04 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
SI0916347T1 (en) 1997-11-18 2003-06-30 Uni-Pharma Kleon Tsetis A.B.E.E. Pharmaceutical injectable solutions containing paracetamol and combinations of paracetamol with other active substances
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
CN1711101A (zh) 2002-10-03 2005-12-21 Pr药品有限公司 孤独症及相似障碍的治疗
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
JP2007525442A (ja) 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2009005352A1 (en) 2007-07-02 2009-01-08 Sime Darby Malaysia Berhad Frying fat composition
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
JP5539310B2 (ja) * 2008-03-31 2014-07-02 フェリング ベスローテン フェンノートシャップ オキシトシン類似体
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
HUE056835T2 (hu) 2022-03-28
JP2013543492A (ja) 2013-12-05
PT3246018T (pt) 2022-01-13
DK2621468T3 (en) 2017-09-11
IL245328B (en) 2022-04-01
TWI532507B (zh) 2016-05-11
WO2012042371A3 (en) 2013-04-04
HK1246170A1 (zh) 2018-09-07
MX2013003365A (es) 2013-07-29
DK3222272T3 (da) 2022-01-24
ES2902418T3 (es) 2022-03-28
PT2621468T (pt) 2017-09-08
ES2905561T3 (es) 2022-04-11
CY1124924T1 (el) 2023-01-05
KR20180123599A (ko) 2018-11-16
RS62873B1 (sr) 2022-02-28
JOP20180102B1 (ar) 2022-03-14
EP4374878A2 (en) 2024-05-29
TW201940188A (zh) 2019-10-16
HUE057187T2 (hu) 2022-04-28
IL225238A0 (en) 2013-06-27
KR20130136467A (ko) 2013-12-12
SMT201700420T1 (it) 2017-11-15
ES2637988T3 (es) 2017-10-18
RU2604690C2 (ru) 2016-12-10
KR101919119B1 (ko) 2018-11-15
BR122021001123B1 (pt) 2021-05-18
EP3222272A1 (en) 2017-09-27
TWI680773B (zh) 2020-01-01
IL245328A0 (en) 2016-06-30
KR102102664B1 (ko) 2020-04-22
EP3936117A1 (en) 2022-01-12
JOP20180102A1 (ar) 2019-01-30
IL245326B (en) 2021-04-29
US20170106043A1 (en) 2017-04-20
RU2013112666A (ru) 2014-11-10
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
NZ609719A (en) 2014-07-25
JOP20180103A1 (ar) 2019-01-30
EP3246018A1 (en) 2017-11-22
TWI750934B (zh) 2021-12-21
LT2621468T (lt) 2017-11-27
BR112013007362A2 (pt) 2016-07-12
RU2737264C2 (ru) 2020-11-26
CY1119245T1 (el) 2018-02-14
CN104906032A (zh) 2015-09-16
RU2016143751A3 (pl) 2020-01-16
JOP20180103B1 (ar) 2022-03-14
TWI650134B (zh) 2019-02-11
JP6250770B2 (ja) 2017-12-20
CN107080832A (zh) 2017-08-22
CN103124554A (zh) 2013-05-29
US20170106044A1 (en) 2017-04-20
JP6038797B2 (ja) 2016-12-07
IL245326A0 (en) 2016-06-30
US20130210746A1 (en) 2013-08-15
RS56220B1 (sr) 2017-11-30
PL3222272T3 (pl) 2022-03-07
LT3222272T (lt) 2021-12-27
CA2812510A1 (en) 2012-04-05
TW201605465A (zh) 2016-02-16
TWI661834B (zh) 2019-06-11
SI2621468T1 (sl) 2017-10-30
AU2011309762A1 (en) 2013-04-04
EP3246018B1 (en) 2021-11-03
HRP20171256T1 (hr) 2017-10-20
EP3222272B1 (en) 2021-11-03
EP4374878B1 (en) 2025-02-12
TW201605466A (zh) 2016-02-16
CN107080832B (zh) 2021-05-07
TW201729797A (zh) 2017-09-01
JO3400B1 (ar) 2019-10-20
SMT202200034T1 (it) 2022-03-21
JP2017048226A (ja) 2017-03-09
MX352949B (es) 2017-12-15
CN107412728A (zh) 2017-12-01
WO2012042371A2 (en) 2012-04-05
TWI746951B (zh) 2021-11-21
AU2011309762B2 (en) 2014-07-17
SI3246018T1 (sl) 2022-02-28
BR112013007362B1 (pt) 2021-05-25
SI3222272T1 (sl) 2022-01-31
EP4374878A3 (en) 2024-07-24
EP2621468A2 (en) 2013-08-07
IL225238B (en) 2018-07-31
EP2621468B1 (en) 2017-06-14
HUE034367T2 (en) 2018-02-28
US20230124105A1 (en) 2023-04-20
PL3246018T3 (pl) 2022-05-02
RU2016143751A (ru) 2018-12-18
DK3246018T3 (da) 2022-01-17
US9566311B2 (en) 2017-02-14
TW202112389A (zh) 2021-04-01
HRP20211969T1 (hr) 2022-03-18

Similar Documents

Publication Publication Date Title
RS62873B1 (sr) Farmaceutski sastav karbetocina
SMT201700008B (it) Composizione farmaceutica
SMT201600350B (it) Composizioni farmaceutiche
BR112013002845A2 (pt) combinação de susbtâncias ativas
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
EE201300005A (et) Ravimkoostis
LT2603232T (lt) Stabilios linaklotido vaisto formos
EP2552212A4 (en) IMPROVED FORMULATION
EP2531023A4 (en) IMPROVED FORMULATION
EP2635269A4 (en) COMBINATION COMPOSITION
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
CO6801722A2 (es) Composiciones farmacéuticas
BR112013008074A2 (pt) combinações farmacêuticas
SMT201500005B (it) Composizione framaceutica inalabile
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
BR112013014291A2 (pt) formulação lipossômica de calcetrapib
FR2955473B1 (fr) Structure de presentoir
DK2598175T3 (da) Radiofarmaceutiske sammensætninger
FR2956419B1 (fr) Elements de construction calorifuges
BR112012029887A2 (pt) composição farmacêutica
FR2955136B1 (fr) Arret de vantail
FI20105327A0 (fi) Farmaseuttinen koostumus
BR112013014710A2 (pt) entrega de compostos funcionais
BR112013013304A2 (pt) composições farmacêuticas
BR112013012833A2 (pt) composições farmacêuticas